M1 KLINIKEN AG (M12.DE) Stock Fundamental Analysis
Europe - FRA:M12 - DE000A0STSQ8 - Common Stock
14.06 EUR
+0.54 (+3.99%)
Taking everything into account, M12 scores 6 out of 10 in our fundamental rating. M12 was compared to 27 industry peers in the Health Care Providers & Services industry. M12 has an excellent financial health rating, but there are some minor concerns on its profitability. M12 is not overvalued while it is showing excellent growth. This is an interesting combination. These ratings could make M12 a good candidate for growth investing.
1. Profitability
1.1 Basic Checks
In the past year M12 was profitable.
In the past year M12 had a positive cash flow from operations.
M12 had positive earnings in each of the past 5 years.
Each year in the past 5 years M12 had a positive operating cash flow.
1.2 Ratios
M12 has a better Return On Assets (8.53%) than 96.30% of its industry peers.
Looking at the Return On Equity, with a value of 15.10%, M12 is in the better half of the industry, outperforming 77.78% of the companies in the same industry.
M12's Return On Invested Capital of 12.86% is amongst the best of the industry. M12 outperforms 92.59% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for M12 is in line with the industry average of 6.10%.
The last Return On Invested Capital (12.86%) for M12 is above the 3 year average (7.72%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.53% | ||
| ROE | 15.1% | ||
| ROIC | 12.86% |
ROA(3y)5.18%
ROA(5y)4.73%
ROE(3y)9.59%
ROE(5y)9.22%
ROIC(3y)7.72%
ROIC(5y)6.16%
1.3 Margins
M12's Profit Margin of 4.72% is fine compared to the rest of the industry. M12 outperforms 70.37% of its industry peers.
In the last couple of years the Profit Margin of M12 has declined.
M12 has a better Operating Margin (7.89%) than 66.67% of its industry peers.
In the last couple of years the Operating Margin of M12 has declined.
M12's Gross Margin of 18.75% is on the low side compared to the rest of the industry. M12 is outperformed by 66.67% of its industry peers.
M12's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 7.89% | ||
| PM (TTM) | 4.72% | ||
| GM | 18.75% |
OM growth 3Y27.08%
OM growth 5Y-5.31%
PM growth 3Y18.61%
PM growth 5Y-17.82%
GM growth 3Y2.18%
GM growth 5Y-14.45%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so M12 is still creating some value.
Compared to 1 year ago, M12 has less shares outstanding
Compared to 5 years ago, M12 has more shares outstanding
M12 has a worse debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 5.14 indicates that M12 is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 5.14, M12 belongs to the top of the industry, outperforming 96.30% of the companies in the same industry.
The Debt to FCF ratio of M12 is 0.71, which is an excellent value as it means it would take M12, only 0.71 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 0.71, M12 belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
A Debt/Equity ratio of 0.07 indicates that M12 is not too dependend on debt financing.
M12 has a Debt to Equity ratio of 0.07. This is amongst the best in the industry. M12 outperforms 96.30% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.07 | ||
| Debt/FCF | 0.71 | ||
| Altman-Z | 5.14 |
ROIC/WACC1.8
WACC7.16%
2.3 Liquidity
A Current Ratio of 1.91 indicates that M12 should not have too much problems paying its short term obligations.
M12's Current ratio of 1.91 is amongst the best of the industry. M12 outperforms 85.19% of its industry peers.
A Quick Ratio of 1.07 indicates that M12 should not have too much problems paying its short term obligations.
M12 has a better Quick ratio (1.07) than 62.96% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.91 | ||
| Quick Ratio | 1.07 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 55.90% over the past year.
M12 shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 7.97% yearly.
M12 shows a small growth in Revenue. In the last year, the Revenue has grown by 7.23%.
The Revenue has been growing by 34.44% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)55.9%
EPS 3Y21.62%
EPS 5Y7.97%
EPS Q2Q%-10.77%
Revenue 1Y (TTM)7.23%
Revenue growth 3Y2.54%
Revenue growth 5Y34.44%
Sales Q2Q%3.58%
3.2 Future
Based on estimates for the next years, M12 will show a quite strong growth in Earnings Per Share. The EPS will grow by 19.44% on average per year.
The Revenue is expected to grow by 8.24% on average over the next years. This is quite good.
EPS Next Y4.33%
EPS Next 2Y14.78%
EPS Next 3Y19.44%
EPS Next 5YN/A
Revenue Next Year5.72%
Revenue Next 2Y6.69%
Revenue Next 3Y6.7%
Revenue Next 5Y8.24%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 17.15, M12 is valued on the expensive side.
M12's Price/Earnings ratio is in line with the industry average.
When comparing the Price/Earnings ratio of M12 to the average of the S&P500 Index (27.30), we can say M12 is valued slightly cheaper.
M12 is valuated correctly with a Price/Forward Earnings ratio of 15.30.
M12's Price/Forward Earnings is on the same level as the industry average.
M12's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 22.73.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 17.15 | ||
| Fwd PE | 15.3 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of M12 indicates a somewhat cheap valuation: M12 is cheaper than 66.67% of the companies listed in the same industry.
74.07% of the companies in the same industry are more expensive than M12, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 9.34 | ||
| EV/EBITDA | 8.12 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
The decent profitability rating of M12 may justify a higher PE ratio.
A more expensive valuation may be justified as M12's earnings are expected to grow with 19.44% in the coming years.
PEG (NY)3.96
PEG (5Y)2.15
EPS Next 2Y14.78%
EPS Next 3Y19.44%
5. Dividend
5.1 Amount
M12 has a Yearly Dividend Yield of 3.75%. Purely for dividend investing, there may be better candidates out there.
M12's Dividend Yield is rather good when compared to the industry average which is at 2.78. M12 pays more dividend than 96.30% of the companies in the same industry.
Compared to an average S&P500 Dividend Yield of 2.45, M12 pays a better dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.75% |
5.2 History
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years1
5.3 Sustainability
DPN/A
EPS Next 2Y14.78%
EPS Next 3Y19.44%
FRA:M12 (9/12/2025, 7:00:00 PM)
14.06
+0.54 (+3.99%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners0.96%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap276.14M
Analysts85
Price Target27.03 (92.25%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.75% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-5.33%
EPS NY rev (3m)-5.33%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.61%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 17.15 | ||
| Fwd PE | 15.3 | ||
| P/S | 0.81 | ||
| P/FCF | 9.34 | ||
| P/OCF | 9.04 | ||
| P/B | 2.6 | ||
| P/tB | 14.82 | ||
| EV/EBITDA | 8.12 |
EPS(TTM)0.82
EY5.83%
EPS(NY)0.92
Fwd EY6.54%
FCF(TTM)1.5
FCFY10.7%
OCF(TTM)1.56
OCFY11.06%
SpS17.27
BVpS5.4
TBVpS0.95
PEG (NY)3.96
PEG (5Y)2.15
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.53% | ||
| ROE | 15.1% | ||
| ROCE | 18.56% | ||
| ROIC | 12.86% | ||
| ROICexc | 15.5% | ||
| ROICexgc | 57.73% | ||
| OM | 7.89% | ||
| PM (TTM) | 4.72% | ||
| GM | 18.75% | ||
| FCFM | 8.71% |
ROA(3y)5.18%
ROA(5y)4.73%
ROE(3y)9.59%
ROE(5y)9.22%
ROIC(3y)7.72%
ROIC(5y)6.16%
ROICexc(3y)9.69%
ROICexc(5y)8.26%
ROICexgc(3y)31.7%
ROICexgc(5y)24.88%
ROCE(3y)11.15%
ROCE(5y)8.88%
ROICexcg growth 3Y38.16%
ROICexcg growth 5Y31.27%
ROICexc growth 3Y22.22%
ROICexc growth 5Y5.12%
OM growth 3Y27.08%
OM growth 5Y-5.31%
PM growth 3Y18.61%
PM growth 5Y-17.82%
GM growth 3Y2.18%
GM growth 5Y-14.45%
F-Score9
Asset Turnover1.81
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.07 | ||
| Debt/FCF | 0.71 | ||
| Debt/EBITDA | 0.23 | ||
| Cap/Depr | 19.3% | ||
| Cap/Sales | 0.29% | ||
| Interest Coverage | 17.5 | ||
| Cash Conversion | 95.72% | ||
| Profit Quality | 184.48% | ||
| Current Ratio | 1.91 | ||
| Quick Ratio | 1.07 | ||
| Altman-Z | 5.14 |
F-Score9
WACC7.16%
ROIC/WACC1.8
Cap/Depr(3y)22.84%
Cap/Depr(5y)24.89%
Cap/Sales(3y)0.41%
Cap/Sales(5y)0.51%
Profit Quality(3y)272.44%
Profit Quality(5y)207.18%
High Growth Momentum
Growth
EPS 1Y (TTM)55.9%
EPS 3Y21.62%
EPS 5Y7.97%
EPS Q2Q%-10.77%
EPS Next Y4.33%
EPS Next 2Y14.78%
EPS Next 3Y19.44%
EPS Next 5YN/A
Revenue 1Y (TTM)7.23%
Revenue growth 3Y2.54%
Revenue growth 5Y34.44%
Sales Q2Q%3.58%
Revenue Next Year5.72%
Revenue Next 2Y6.69%
Revenue Next 3Y6.7%
Revenue Next 5Y8.24%
EBIT growth 1Y69.16%
EBIT growth 3Y30.31%
EBIT growth 5Y27.31%
EBIT Next Year28.34%
EBIT Next 3Y33.77%
EBIT Next 5YN/A
FCF growth 1Y49.16%
FCF growth 3Y27.23%
FCF growth 5YN/A
OCF growth 1Y46.7%
OCF growth 3Y24.88%
OCF growth 5YN/A